MA28883B1 - Procede de preparation de 4-{4-[({[4-chloro-3-(trifluoromethyl) phenyl]amino}carbonyl) amino]phenoxy}-n-methylpyridine-2-carboxamide - Google Patents

Procede de preparation de 4-{4-[({[4-chloro-3-(trifluoromethyl) phenyl]amino}carbonyl) amino]phenoxy}-n-methylpyridine-2-carboxamide

Info

Publication number: MA28883B1
Authority: MA; Morocco
Prior art keywords: amino; methylpyridine; carboxamide; phenoxy; trifluoromethyl
Prior art date: 2004-09-29

Application number

MA29788A

Other languages

English (en)

Inventor

Michael Loegers

Reinhold Gehring

Oliver Kuhn

Mike Matthaeus

Klaus Mohrs

Matthias Mueller-Gliemann

Juergen Stiehl

Mathias Berwe

Jana Lenz

Werner Heilmann

Original Assignee

Bayer Schering Pharma Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-09-29

Filing date

2007-03-30

Publication date

2007-09-03

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35457568&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA28883(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-03-30 Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag

2007-09-03 Publication of MA28883B1 publication Critical patent/MA28883B1/fr

Links

MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 title 1
238000004519 manufacturing process Methods 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pyridine Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Developing Agents For Electrophotography (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Plant Substances (AREA)

MA29788A 2004-09-29 2007-03-30 Procede de preparation de 4-{4-[({[4-chloro-3-(trifluoromethyl) phenyl]amino}carbonyl) amino]phenoxy}-n-methylpyridine-2-carboxamide MA28883B1 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP04023131		2004-09-29

Publications (1)

Publication Number	Publication Date
MA28883B1 true MA28883B1 (fr)	2007-09-03

Family

ID=35457568

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA29788A MA28883B1 (fr)	2004-09-29	2007-03-30	Procede de preparation de 4-{4-[({[4-chloro-3-(trifluoromethyl) phenyl]amino}carbonyl) amino]phenoxy}-n-methylpyridine-2-carboxamide

Country Status (34)

Country	Link
US (1)	US8124782B2 (fr)
EP (1)	EP1797037B1 (fr)
JP (2)	JP2008514657A (fr)
KR (1)	KR101263032B1 (fr)
CN (1)	CN101052619B (fr)
AR (1)	AR053973A1 (fr)
AU (1)	AU2005289099B2 (fr)
BR (1)	BRPI0515944B1 (fr)
CA (1)	CA2581835C (fr)
CU (1)	CU23754B7 (fr)
CY (1)	CY1116126T1 (fr)
DK (1)	DK1797037T3 (fr)
DO (1)	DOP2005000183A (fr)
EC (1)	ECSP077357A (fr)
ES (1)	ES2532377T3 (fr)
GT (1)	GT200500269A (fr)
HN (1)	HN2005000768A (fr)
HR (1)	HRP20150295T1 (fr)
IL (1)	IL182046A0 (fr)
MA (1)	MA28883B1 (fr)
MY (1)	MY149873A (fr)
NO (1)	NO339647B1 (fr)
NZ (1)	NZ554119A (fr)
PE (5)	PE20091587A1 (fr)
PL (1)	PL1797037T3 (fr)
PT (1)	PT1797037E (fr)
SG (1)	SG155997A1 (fr)
SI (1)	SI1797037T1 (fr)
SV (1)	SV2006002243A (fr)
TW (1)	TWI382973B (fr)
UA (1)	UA90691C2 (fr)
UY (1)	UY29143A1 (fr)
WO (1)	WO2006034796A1 (fr)
ZA (1)	ZA200702511B (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1158985B1 (fr)	1999-01-13	2011-12-28	Bayer HealthCare LLC	DIPHENYLE UREES A SUBSTITUTION OMEGA-CARBOXY ARYLE EN TANT QU'INHIBITEURS DE LA KINASE p38
US8124630B2 (en)	1999-01-13	2012-02-28	Bayer Healthcare Llc	ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
SI1478358T1 (sl)	2002-02-11	2013-09-30	Bayer Healthcare Llc	Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi
EP1636585B2 (fr)	2003-05-20	2012-06-13	Bayer HealthCare LLC	Diaryl-urees presentant une activite d'inhibition des kinases
EP1663978B1 (fr)	2003-07-23	2007-11-28	Bayer Pharmaceuticals Corporation	Omega-carboxyaryldiphenyluree fluoro-subtituee pour le traitement et la prevention de maladies et d'etats pathologiques
EP1797037B1 (fr)	2004-09-29	2014-12-17	Bayer HealthCare LLC	Procede de preparation de 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-n-methylpyridine-2-carboxamide
DK1797038T3 (da) *	2004-09-29	2012-09-03	Bayer Pharma AG	Termodynamisk stabil form af bay 43-9006-tosylat
ATE482693T1 (de)	2005-03-07	2010-10-15	Bayer Schering Pharma Ag	Pharmazeutische zusammensetzung mit einem omega- carboxyaryl-substituierten diphenylharnstoff zur behandlung von krebs
AR062927A1 (es)	2006-10-11	2008-12-17	Bayer Healthcare Ag	4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
EP2089363A1 (fr) *	2006-11-14	2009-08-19	Bayer Schering Pharma Aktiengesellschaft	Polymorphe ii de 4-[4-({[4-chloro-3-(trifluorométhyl)phényl]carbamoyl}amino)-3-fluorophénoxy]-n-méthylpyridine-2-carboxamide
NZ583790A (en)	2007-09-10	2012-04-27	Cipla Ltd	Process for the preparation the raf kinase inhibitor sorafenib and intermediates for use in the process
WO2009054004A2 (fr) *	2007-10-22	2009-04-30	Natco Pharma Limited	Nouveau procédé pour la préparation du sorafénib
EP2231612A1 (fr)	2008-01-17	2010-09-29	Sicor, Inc.	Polymorphes de forme iii de tosylate de sorafénib, solvate de méthanol tosylate de sorafénib et solvate d'éthanol tosylate de sorafénib, et procédés de préparation associés
WO2009111061A1 (fr) *	2008-03-06	2009-09-11	Sicor Inc.	Procédé de préparation du sorafénib et ses sels
CN103254126A (zh) *	2008-09-19	2013-08-21	苏州泽璟生物制药有限公司	氘代的ω-二苯基脲及衍生物以及包含该化合物的药物组合物
CA2775296A1 (fr)	2009-09-24	2011-03-31	Ranbaxy Laboratories Limited	Polymorphes de sels d'addition acide de sorafenib
WO2011036647A1 (fr)	2009-09-24	2011-03-31	Ranbaxy Laboratories Limited	Procédé de préparation de tosylate de sorafénib
WO2011058522A1 (fr)	2009-11-12	2011-05-19	Ranbaxy Laboratories Limited	Sel d'ethylsulfonate de sorafenib et son procede de preparation
WO2011076711A2 (fr)	2009-12-23	2011-06-30	Ratiopharm Gmbh	Polymorphes de 4-[4-[[4-chloro-3-(trifluorométhyl)phényl]carbamoylamino]phénoxy]-n-méthylpyridine-2-carboxamide
PL2528899T3 (pl)	2010-01-29	2015-02-27	Ranbaxy Laboratories Ltd	Solwat sorafenibu z dimetylosulfotlenkiem
CN102190616B (zh) *	2010-03-18	2015-07-29	苏州泽璟生物制药有限公司	一种氘代的ω-二苯基脲的合成及生产的方法和工艺
AR081060A1 (es)	2010-04-15	2012-06-06	Bayer Schering Pharma Ag	Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
CN102617458A (zh) *	2010-05-18	2012-08-01	张南	抗癌用化合物的制备方法
CA2805874A1 (fr)	2010-07-19	2012-01-26	Bayer Healthcare Llc	Associations medicamenteuses contenant une omega-carboxyaryl diphenyluree fluorosubstituee utilisees pour le traitement et la prevention de maladies et d'affections
US9381177B2 (en)	2010-10-01	2016-07-05	Bayer Intellectual Property Gmbh	Substituted N-(2-arylamino)aryl sulfonamide-containing combinations
WO2012071425A1 (fr)	2010-11-22	2012-05-31	Teva Pharmaceutical Industries Ltd.	Formes à l'état solide de bésylate de sorafénib et procédés de préparation
EP2559431A1 (fr)	2011-08-17	2013-02-20	Ratiopharm GmbH	Composition pharmaceutique comportant du 4-[4-[[4-Chloro-3-(trifluoromethyl)phényl]carbamoylamino]phénoxy]-N-méthyl-pyridine-2-carboxamide
CN103664771B (zh) *	2012-09-19	2016-03-30	齐鲁制药有限公司	索拉非尼的晶型a及其制备方法
WO2014118807A1 (fr) *	2013-02-04	2014-08-07	Intas Pharmaceuticals Limited	Nouveau procédé de préparation de tosylate de sorafénib de forme iii
CN104710354A (zh) *	2013-12-13	2015-06-17	江苏豪森药业股份有限公司	高纯度索拉非尼的制备方法
CN104761492A (zh) *	2014-01-03	2015-07-08	正大天晴药业集团股份有限公司	对甲苯磺酸索拉非尼的晶型及其制备方法
CN104177292A (zh) *	2014-08-08	2014-12-03	亿腾药业（泰州）有限公司	一种工业化生产甲苯磺酸索拉非尼多晶型ⅰ的方法
CN110204483B (zh) *	2014-12-01	2021-06-29	石药集团中奇制药技术（石家庄）有限公司	一种甲苯磺酸索拉非尼新晶型及其制备方法
EP3109236B1 (fr)	2015-06-23	2017-08-09	F.I.S.- Fabbrica Italiana Sintetici S.p.A.	Procédé évolutif pour la préparation de solvate d'éthanol tosylate de sorafénibe et tosylate de sorafénibe forme iii
CN105181844A (zh) *	2015-09-11	2015-12-23	江苏嘉逸医药有限公司	一种高效液相色谱法测定甲苯磺酸索拉非尼含量和有关物质的方法
CN105585523A (zh) *	2015-12-29	2016-05-18	上海北卡医药技术有限公司	一种对甲苯磺酸索拉非尼的新晶型及其制备方法和用途
CN107840823B (zh) *	2016-09-20	2021-08-17	意大利合成制造有限公司	用于制备甲苯磺酸索拉非尼乙醇溶剂化物和iii型甲苯磺酸索拉非尼的可变规模的方法
CN107915676A (zh) *	2017-10-26	2018-04-17	魏海霞	索拉非尼的制备方法
CN109796400B (zh) *	2017-11-16	2022-07-29	四川科伦药物研究院有限公司	一种甲苯磺酸索拉菲尼晶型及其制备方法
CN113773249A (zh) *	2020-06-10	2021-12-10	杭州中美华东制药有限公司	索拉非尼游离碱晶型Form X及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
LU86960A1 (fr) *	1987-07-31	1989-03-08	Oreal	Procede de preparation de piperidino-6 diamino-2,4 pyrimidine oxyde-3 et composes nouveaux
JPH02934A (ja) *	1988-05-27	1990-01-05	Konica Corp	非線形光学材料
JP2971291B2 (ja) *	1993-06-02	1999-11-02	田辺製薬株式会社	光学活性２−アミノ酪酸の製法
JP3866323B2 (ja) *	1996-03-27	2007-01-10	ポーラ化成工業株式会社	新規ｎ−ベンジルベンズアミド誘導体
JPH09316069A (ja) *	1996-03-28	1997-12-09	Ajinomoto Co Inc	新規キサントン誘導体
PT1140840E (pt) *	1999-01-13	2006-05-31	Bayer Pharmaceuticals Corp	Difenilureias substituidas com (.)-carboxiarilo como inibidores de raf-quinase
US8124630B2 (en)	1999-01-13	2012-02-28	Bayer Healthcare Llc	ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP1140840B1 (fr)	1999-01-13	2006-03-22	Bayer Pharmaceuticals Corp.	Diphenylurees a substituants -g(v)-carboxyaryles, inhibitrices de kinase raf
GB2367816A (en) *	2000-10-09	2002-04-17	Bayer Ag	Urea- and thiourea-containing derivatives of beta-amino acids
WO2003047579A1 (fr) *	2001-12-03	2003-06-12	Bayer Pharmaceuticals Corporation	Composes de type uree aryle combines a d'autres agents cytostatiques ou cytotoxiques et servant a traiter des cancers humains
US20030207872A1 (en)	2002-01-11	2003-11-06	Bayer Corporation	Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
DE10203086A1 (de) *	2002-01-28	2003-07-31	Bayer Ag	5-Ring Heterozyklen
SI1478358T1 (sl) *	2002-02-11	2013-09-30	Bayer Healthcare Llc	Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi
ATE501154T1 (de) *	2002-08-13	2011-03-15	Sandoz Ag	Ein cefdinir-zwischenprodukt
ATE374199T1 (de) *	2002-10-21	2007-10-15	Kirin Brewery	N-ä2-chlor-4-((6,7-dimethoxy-4- chinolyl)oxy)phenylü-n'-(5-methyl-3- isoxazolyl)harnstoffsalzin kristalliner form
EP1636585B2 (fr) *	2003-05-20	2012-06-13	Bayer HealthCare LLC	Diaryl-urees presentant une activite d'inhibition des kinases
EP1797037B1 (fr)	2004-09-29	2014-12-17	Bayer HealthCare LLC	Procede de preparation de 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-n-methylpyridine-2-carboxamide

2005
- 2005-09-20 EP EP05794785.5A patent/EP1797037B1/fr not_active Expired - Lifetime
- 2005-09-20 HR HRP20150295TT patent/HRP20150295T1/hr unknown
- 2005-09-20 CN CN2005800373684A patent/CN101052619B/zh not_active Expired - Lifetime
- 2005-09-20 ES ES05794785.5T patent/ES2532377T3/es not_active Expired - Lifetime
- 2005-09-20 SI SI200531947T patent/SI1797037T1/sl unknown
- 2005-09-20 KR KR1020077009652A patent/KR101263032B1/ko not_active Expired - Fee Related
- 2005-09-20 UA UAA200704750A patent/UA90691C2/ru unknown
- 2005-09-20 US US11/664,332 patent/US8124782B2/en active Active
- 2005-09-20 PL PL05794785T patent/PL1797037T3/pl unknown
- 2005-09-20 AU AU2005289099A patent/AU2005289099B2/en not_active Ceased
- 2005-09-20 DK DK05794785T patent/DK1797037T3/en active
- 2005-09-20 CA CA2581835A patent/CA2581835C/fr not_active Expired - Lifetime
- 2005-09-20 BR BRPI0515944-0A patent/BRPI0515944B1/pt active IP Right Grant
- 2005-09-20 NZ NZ554119A patent/NZ554119A/en not_active IP Right Cessation
- 2005-09-20 JP JP2007533904A patent/JP2008514657A/ja active Pending
- 2005-09-20 SG SG200906449-4A patent/SG155997A1/en unknown
- 2005-09-20 PT PT05794785T patent/PT1797037E/pt unknown
- 2005-09-20 WO PCT/EP2005/010118 patent/WO2006034796A1/fr not_active Ceased
- 2005-09-23 DO DO2005000183A patent/DOP2005000183A/es unknown
- 2005-09-26 AR ARP050104020A patent/AR053973A1/es active IP Right Grant
- 2005-09-27 MY MYPI20054553A patent/MY149873A/en unknown
- 2005-09-28 PE PE2009000512A patent/PE20091587A1/es active IP Right Grant
- 2005-09-28 TW TW094133620A patent/TWI382973B/zh not_active IP Right Cessation
- 2005-09-28 PE PE2009000509A patent/PE20091584A1/es active IP Right Grant
- 2005-09-28 UY UY29143A patent/UY29143A1/es not_active IP Right Cessation
- 2005-09-28 GT GT200500269A patent/GT200500269A/es unknown
- 2005-09-28 PE PE2009000511A patent/PE20091586A1/es not_active Application Discontinuation
- 2005-09-28 PE PE2009000510A patent/PE20091585A1/es active IP Right Grant
- 2005-09-28 PE PE2005001144A patent/PE20060825A1/es active IP Right Grant
- 2005-09-29 SV SV2005002243A patent/SV2006002243A/es active IP Right Grant
- 2005-10-04 HN HN2005000768A patent/HN2005000768A/es unknown
2007
- 2007-03-20 IL IL182046A patent/IL182046A0/en active IP Right Grant
- 2007-03-26 CU CU20070069A patent/CU23754B7/es active IP Right Grant
- 2007-03-27 ZA ZA200702511A patent/ZA200702511B/en unknown
- 2007-03-28 EC EC2007007357A patent/ECSP077357A/es unknown
- 2007-03-30 MA MA29788A patent/MA28883B1/fr unknown
- 2007-04-26 NO NO20072173A patent/NO339647B1/no unknown
2012
- 2012-11-02 JP JP2012242831A patent/JP5583190B2/ja not_active Expired - Lifetime
2015
- 2015-03-17 CY CY20151100268T patent/CY1116126T1/el unknown

Also Published As

Publication number	Publication date
BRPI0515944B1 (pt)	2021-11-09
AR053973A1 (es)	2007-05-30
PE20091586A1 (es)	2009-10-31
HN2005000768A (es)	2010-09-17
CA2581835C (fr)	2012-12-18
NZ554119A (en)	2010-07-30
CN101052619B (zh)	2012-02-22
JP2008514657A (ja)	2008-05-08
HRP20150295T1 (hr)	2015-05-22
ECSP077357A (es)	2007-04-26
CN101052619A (zh)	2007-10-10
KR20070058676A (ko)	2007-06-08
DK1797037T3 (en)	2015-03-30
KR101263032B1 (ko)	2013-05-09
UY29143A1 (es)	2006-04-28
SI1797037T1 (sl)	2015-06-30
SG155997A1 (en)	2009-10-29
CY1116126T1 (el)	2017-02-08
WO2006034796A1 (fr)	2006-04-06
HK1113484A1 (en)	2008-10-03
SV2006002243A (es)	2006-10-13
UA90691C2 (en)	2010-05-25
CA2581835A1 (fr)	2006-04-06
PT1797037E (pt)	2015-03-17
GT200500269A (es)	2006-05-11
EP1797037B1 (fr)	2014-12-17
AU2005289099A1 (en)	2006-04-06
MY149873A (en)	2013-10-31
NO20072173L (no)	2007-06-14
PE20091585A1 (es)	2009-10-31
EP1797037A1 (fr)	2007-06-20
JP5583190B2 (ja)	2014-09-03
IL182046A0 (en)	2007-07-24
JP2013067625A (ja)	2013-04-18
PE20091587A1 (es)	2009-11-05
US20080262236A1 (en)	2008-10-23
PL1797037T3 (pl)	2015-07-31
DOP2005000183A (es)	2006-03-31
ES2532377T3 (es)	2015-03-26
US8124782B2 (en)	2012-02-28
CU23754B7 (es)	2012-01-31
TWI382973B (zh)	2013-01-21
CU20070069A7 (es)	2010-11-27
TW200626551A (en)	2006-08-01
NO339647B1 (no)	2017-01-16
ZA200702511B (en)	2008-07-30
PE20060825A1 (es)	2006-10-20
BRPI0515944A (pt)	2008-08-12
AU2005289099B2 (en)	2012-07-19
PE20091584A1 (es)	2009-10-28

Publication	Publication Date	Title
MA28883B1 (fr)	2007-09-03	Procede de preparation de 4-{4-[({[4-chloro-3-(trifluoromethyl) phenyl]amino}carbonyl) amino]phenoxy}-n-methylpyridine-2-carboxamide
UA91520C2 (en)	2010-08-10	Thermodynamically stable form of tosylate
LTC3170818I2 (lt)	2023-05-25	Kietos 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzoinės rūgšties formos
MA30878B1 (fr)	2009-11-02	4-[4-({[4-chloro-3-(trifluorométhyl) phényl]carbamoyl}amino)-3-fluorophénoxy]-n-méthylpyridine-2-carboxamide monohydraté
IL182095A0 (en)	2007-07-24	Process for making phenoxy benzamide compounds
IL222348A0 (en)	2012-12-31	Process for the preparation of 4- {4-[({[4 -chloro-3 -(trifluoromethyl)-phenyl]amino}carbonyl)amino]-3-fluorophenoxy}-n-methylpyridine-2-carboxamide, its salts and monohydrate
EP1854539A4 (fr)	2009-04-08	Materiau catalytique et procede pour sa preparation
DK1760156T3 (da)	2013-03-18	Materialer og fremgangsmåder til effektiv mælkesyrefremstilling
EP2007213A4 (fr)	2011-07-06	Procédé permettant de préparer une protéine de lactosérum modifiée et déshydratée
FI20031904L (fi)	2005-06-24	Menetelmä lignoselluloosatuotteen muokkaamiseksi
IL182996A0 (en)	2007-08-19	Process for preparing quinoline compounds and products obtained therefrom
DE602006014300D1 (de)	2010-06-24	Verfahren und system für medienunabhängiges handover unter verwendung des oamp-protokolls
EP1537083A4 (fr)	2006-11-22	Nicotinate de s-(-)-amlodipine, et son procede de preparation
EP1812906A4 (fr)	2014-08-13	Appareil d'edition pleine page, procede d'edition pleine page et programme d'edition pleine page
FR2876998B1 (fr)	2007-01-19	Procede de preparation de gamma-liv205
IL172169A0 (en)	2009-02-11	Processes for preparing (2s) - 3 - (4 - {2 - [amino] - 2 - oxoethoxy}
FR2886650B1 (fr)	2007-08-24	Procede d'enrichissement de residus lignocellulosiques en proteines de levure
FR2876689B1 (fr)	2008-02-22	Nouveau procede et intermediaires de preparation de derives de n-(1-benzhydryl-azetidin-3-yl)-n-phenyl-methylsulfonamide
FR2886102B1 (fr)	2007-07-27	Procede de fabrication ou de pre-assemblage d'un filet, notamment un filet de peche, filet de peche ainsi obtenu
DE602005009968D1 (de)	2008-11-06	Verfahren zur holzverarbeitung
FR2879895B1 (fr)	2007-03-16	Procede de fabrication ou pre-assemblage d'un filet, notamment un filet de peche, filet de peche ainsi obtenu
HK1088300A (en)	2006-11-03	Processes for preparing (2s)-3-(4-{2-[amino]-2-oxoethoxy}phenyl)-2-ethoxypropanoic acid derivatives
ZA200702609B (en)	2008-11-26	Process for making phenoxy benzamide compounds
HK1107334A (en)	2008-04-03	Process for making phenoxy benzamide compounds
FR2881319B3 (fr)	2007-04-06	Procede de fabrication ou de pre-assemblage d'un filet, notamment un filet de peche, filet de peche ainsi obtenu